Pledg­ing a come­back, Ac­er ax­es pre-com­mer­cial ops, chops staffers in wake of CRL

Days ago the FDA slammed its door on Ac­er Ther­a­peu­tics’ pitch for celipro­lol, block­ing any path to mar­ket that the com­pa­ny saw for the old be­ta block­er. Ex­ecs now say they are nix­ing all pre-com­mer­cial ac­tiv­i­ties in the af­ter­math, which is al­so claim­ing al­most two-thirds of its work­force.

But they are not giv­ing up on that lead pro­gram. By bring­ing the head­count down to 19 from 48, Ac­er hopes to free up re­sources for the de­vel­op­ment of celipro­lol as well as two oth­er pipeline projects. The cash run­way is ex­pect­ed to ex­tend through the end of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER